{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:51:26Z","timestamp":1792601486565,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-026-03176-2","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:58:15Z","timestamp":1775746695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diabetes-related differences in body composition and their prognostic value among patients with heart failure and preserved ejection fraction: a cardiac-MRI-based study"],"prefix":"10.1186","volume":"25","author":[{"given":"Si-Yu","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yan","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Gang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"issue":"9","key":"3176_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","volume":"11","author":"BA Borlaug","year":"2014","unstructured":"Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11(9):507\u201315.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"3176_CR2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.recesp.2024.04.019","volume":"78","author":"M Anguita G\u00e1mez","year":"2025","unstructured":"Anguita G\u00e1mez M, Bonilla Palomas JL, Recio Mayoral A, et al. Outcomes of patients with heart failure followed in units accredited by the SEC-excelente-IC quality program according to the type of unit. Rev Esp Cardiol. 2025;78(1):12\u201321.","journal-title":"Rev Esp Cardiol"},{"issue":"1","key":"3176_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1186\/s12933-025-02995-z","volume":"24","author":"P Gil-Millan","year":"2025","unstructured":"Gil-Millan P, Gimeno-Orna JA, Rodriguez-Padial L, et al. HFpEF as the predominant and underrecognized heart failure phenotype in type 2 diabetes: evidence from the DIABET-IC study. Cardiovasc Diabetol. 2025;24(1):419.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"3176_CR4","first-page":"485","volume":"10","author":"K Huynh","year":"2022","unstructured":"Huynh K, Ayers C, Butler J, et al. Association between thigh muscle fat infiltration and incident heart failure: the health ABC study. JACC: Heart Fail. 2022;10(7):485\u201393.","journal-title":"JACC: Heart Fail"},{"key":"3176_CR5","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2147\/DMSO.S186600","volume":"12","author":"J Mesinovic","year":"2019","unstructured":"Mesinovic J, Zengin A, De Courten B, et al. Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship. Diabetes Metab Syndr Obes Targets Ther. 2019;12:1057\u201372.","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"issue":"1","key":"3176_CR6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12933-025-02949-5","volume":"24","author":"G Armentaro","year":"2025","unstructured":"Armentaro G, Vitale C, Cassano V, et al. Prognostic role of sarcopenia in heart failure patients. Cardiovasc Diabetol. 2025;24(1):411.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3176_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12933-025-02714-8","volume":"24","author":"W Liu","year":"2025","unstructured":"Liu W, Zhang H, Wang X, et al. Combined effect of skeletal muscle mass loss and elevated insulin resistance on heart failure risk in older adults: a community-based longitudinal cohort study. Cardiovasc Diabetol. 2025;24(1):157.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3176_CR8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12933-025-02639-2","volume":"24","author":"K Shi","year":"2025","unstructured":"Shi K, Zhang G, Xu R, et al. Association of body composition with left ventricular remodeling and outcomes in diabetic heart failure with reduced ejection fraction: assessment of sarcopenic obesity using cardiac MRI. Cardiovasc Diabetol. 2025;24(1):79.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"3176_CR9","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/dom.15338","volume":"26","author":"J Boonpor","year":"2024","unstructured":"Boonpor J, Pell JP, Ho FK, et al. In people with type 2 diabetes, sarcopenia is associated with the incidence of cardiovascular disease: a prospective cohort study from the UK biobank. Diabetes Obes Metabolism. 2024;26(2):524\u201331.","journal-title":"Diabetes Obes Metabolism"},{"issue":"6","key":"3176_CR10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jchf.2025.01.016","volume":"13","author":"DD Mendon\u00e7a","year":"2025","unstructured":"Mendon\u00e7a DD, da Silva WVR, Souza GC, et al. Body composition and survival in patients with heart failure: a systematic review and meta-analysis. JACC Heart Fail. 2025;13(6):943\u201354.","journal-title":"JACC Heart Fail"},{"issue":"2","key":"3176_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41569-025-01237-9","volume":"23","author":"N Suthahar","year":"2026","unstructured":"Suthahar N. Redefining heart failure subtypes according to skeletal muscle mass. Nat Reviews Cardiol. 2026;23(2):79\u201380.","journal-title":"Nat Reviews Cardiol"},{"issue":"1","key":"3176_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12933-020-01109-1","volume":"19","author":"L Nesti","year":"2020","unstructured":"Nesti L, Pugliese NR, Sciuto P, et al. Type 2 diabetes and reduced exercise tolerance: a review of the literature through an integrated physiology approach. Cardiovasc Diabetol. 2020;19(1):134.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"3176_CR13","doi-asserted-by":"publisher","first-page":"e009238","DOI":"10.1161\/CIRCHEARTFAILURE.121.009238","volume":"15","author":"G van Woerden","year":"2022","unstructured":"van Woerden G, van Veldhuisen DJ, Manintveld OC, et al. Epicardial adipose tissue and outcome in heart failure with mid-range and preserved ejection fraction. Circ Heart Fail. 2022;15(3):e009238.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"3176_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12872-025-04591-1","volume":"25","author":"M Wu","year":"2025","unstructured":"Wu M, Lai W, Huo X, et al. Association of visceral adiposity index (VAI) with prognosis in patients with metabolic syndrome and heart failure with reduced ejection fraction. BMC Cardiovasc Disord. 2025;25(1):160.","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"3176_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jcmg.2023.07.014","volume":"17","author":"AC Souza","year":"2024","unstructured":"Souza AC, do A H, Rosenthal MH, Moura FA, et al. Body composition, coronary microvascular dysfunction, and future risk of cardiovascular events including heart failure. JACC Cardiovasc Imaging. 2024;17(2):179\u201391.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"36","key":"3176_CR16","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"2","key":"3176_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255\u2013323.","journal-title":"Eur Heart J"},{"issue":"12","key":"3176_CR18","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/eurjpc\/zwaf028","volume":"32","author":"C Huang","year":"2025","unstructured":"Huang C, Li Y, Xu Y, et al. Body mass index, regional adipose deposition, and clinical outcomes in non-ischaemic dilated cardiomyopathy: a prospective cohort study. Eur J Prev Cardiol. 2025;32(12):1043\u201353.","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"3176_CR19","first-page":"203","volume":"14","author":"S Selvaraj","year":"2021","unstructured":"Selvaraj S, Kim J, Ansari BA, et al. Body composition, natriuretic peptides, and adverse outcomes in heart failure with preserved and reduced ejection fraction. JACC: Cardiovasc Imaging. 2021;14(1):203\u201315.","journal-title":"JACC: Cardiovasc Imaging"},{"issue":"1","key":"3176_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12933-023-02109-7","volume":"23","author":"K Shi","year":"2024","unstructured":"Shi K, Zhang G, Fu H, et al. Reduced thoracic skeletal muscle size is associated with adverse outcomes in diabetes patients with heart failure and reduced ejection fraction: quantitative analysis of sarcopenia by using cardiac MRI. Cardiovasc Diabetol. 2024;23(1):28.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"3176_CR21","doi-asserted-by":"publisher","first-page":"e009322","DOI":"10.1161\/CIRCHEARTFAILURE.121.009322","volume":"15","author":"S Mirzai","year":"2022","unstructured":"Mirzai S, Eck BL, Chen PH, et al. Current approach to the diagnosis of sarcopenia in heart failure: a narrative review on the role of clinical and imaging assessments. Circ Heart Fail. 2022;15(10):e009322.","journal-title":"Circ Heart Fail"},{"issue":"6","key":"3176_CR22","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1002\/jcsm.12631","volume":"11","author":"P Janovska","year":"2020","unstructured":"Janovska P, Melenovsky V, Svobodova M, et al. Dysregulation of epicardial adipose tissue in cachexia due to heart failure: the role of natriuretic peptides and cardiolipin. J Cachexia Sarcopenia Muscle. 2020;11(6):1614\u201327.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"6","key":"3176_CR23","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3390\/cells11061039","volume":"11","author":"ME Soto","year":"2022","unstructured":"Soto ME, P\u00e9rez-Torres I, Rubio-Ruiz ME, et al. Interconnection between cardiac cachexia and heart failure-protective role of cardiac obesity. Cells. 2022;11(6):1039.","journal-title":"Cells"},{"issue":"1","key":"3176_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12933-025-02688-7","volume":"24","author":"N Menghoum","year":"2025","unstructured":"Menghoum N, Badii MC, Leroy M, et al. Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2025;24(1):134.","journal-title":"Cardiovasc Diabetol"},{"issue":"24","key":"3176_CR25","doi-asserted-by":"publisher","first-page":"e036789","DOI":"10.1161\/JAHA.124.036789","volume":"13","author":"W Wang","year":"2024","unstructured":"Wang W, Gao Y, Wang J, et al. Prognostic value of epicardial adipose tissue in heart failure with mid-range and preserved ejection fraction: a multicenter study. J Am Heart Association. 2024;13(24):e036789.","journal-title":"J Am Heart Association"},{"issue":"1","key":"3176_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12944-025-02439-3","volume":"24","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Su X, Tan H, et al. Association between metabolic score for visceral fat index and BMI-adjusted skeletal muscle mass index in American adults. Lipids Health Dis. 2025;24(1):29.","journal-title":"Lipids Health Dis"},{"issue":"2","key":"3176_CR27","doi-asserted-by":"publisher","first-page":"pbac013","DOI":"10.1093\/pcmedi\/pbac013","volume":"5","author":"X Liu","year":"2022","unstructured":"Liu X, Yue J. Precision intervention for sarcopenia. Precision Clin Med. 2022;5(2):pbac013.","journal-title":"Precision Clin Med"},{"key":"3176_CR28","doi-asserted-by":"publisher","first-page":"1375610","DOI":"10.3389\/fendo.2024.1375610","volume":"15","author":"Z Liu","year":"2024","unstructured":"Liu Z, Guo Y, Zheng C. Type 2 diabetes mellitus related sarcopenia: a type of muscle loss distinct from sarcopenia and disuse muscle atrophy. Front Endocrinol. 2024;15:1375610.","journal-title":"Front Endocrinol"},{"issue":"20","key":"3176_CR29","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1080\/10408398.2024.2382348","volume":"65","author":"R Qiao","year":"2025","unstructured":"Qiao R, Guo J, Zhang C, et al. Diabetes-induced muscle wasting: molecular mechanisms and promising therapeutic targets. Crit Rev Food Sci Nutr. 2025;65(20):4007\u201323.","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"1","key":"3176_CR30","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1186\/s12967-025-06964-8","volume":"23","author":"AQ Mohammed","year":"2025","unstructured":"Mohammed AQ, Luo Y, Chen Y, et al. Association of systemic immune-inflammation index with adverse outcomes in heart failure and preserved ejection fraction. J Translational Med. 2025;23(1):957.","journal-title":"J Translational Med"},{"issue":"20","key":"3176_CR31","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.jacc.2025.07.052","volume":"86","author":"M Packer","year":"2025","unstructured":"Packer M, Lam CSP, Butler J, et al. Is type 2 diabetes a modifiable risk factor for the evolution and progression of heart failure with a preserved ejection fraction?. JACC. 2025;86(20):1917\u201331.","journal-title":"JACC"},{"issue":"7","key":"3176_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","volume":"85","author":"CM Kramer","year":"2025","unstructured":"Kramer CM, Borlaug BA, Zile MR, et al. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy. J Am Coll Cardiol. 2025;85(7):699\u2013706.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3176_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-023-02096-9","volume":"23","author":"D Garc\u00eda-Vega","year":"2024","unstructured":"Garc\u00eda-Vega D, S\u00e1nchez-L\u00f3pez D, Rodr\u00edguez-Carnero G, et al. Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network. Cardiovasc Diabetol. 2024;23(1):1.","journal-title":"Cardiovasc Diabetol"},{"key":"3176_CR34","doi-asserted-by":"crossref","unstructured":"Tannous L, Tated R, Ramesh J, et al. The obesity paradox in heart failure with preserved ejection fraction: untangling body composition, inflammation, and outcomes. Cardiology in Review; 2025.","DOI":"10.1097\/CRD.0000000000001106"},{"key":"3176_CR35","doi-asserted-by":"publisher","first-page":"112924","DOI":"10.1016\/j.diabres.2025.112924","volume":"229","author":"D Pantazopoulos","year":"2025","unstructured":"Pantazopoulos D, Gouveri E, Papazoglou D, et al. GLP-1 receptor agonists and sarcopenia: weight loss at a cost? A brief narrative review. Diabetes Res Clin Pract. 2025;229:112924.","journal-title":"Diabetes Res Clin Pract"},{"key":"3176_CR36","doi-asserted-by":"crossref","unstructured":"Chao CT, Kovesdy CP, Merchant RA. Sarcopenia, sarcopenic obesity, and frailty in individuals with chronic kidney disease: a comprehensive review. Kidney Research and Clinical Practice; 2025.","DOI":"10.23876\/j.krcp.24.207"},{"key":"3176_CR37","unstructured":"Cuzick J. Interaction, subgroup analysis and sample size. IARC Scientific; 1999. pp. 109\u201321. 148."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03176-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03176-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03176-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:20:12Z","timestamp":1779409212000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03176-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3176"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03176-2","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"8 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Biomedical Research Ethics Committees of West China Hospital and was complied with the Declaration of Helsinki. Written informed consent was waived because of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"157"}}